●AIM:To compare the success rate and complications of adjuvant use of mitomycin C and triamcinoloneimpregnated biodegradable nasal packing(TABP)in endoscopic dacryocystorhinostomy(DCR).And to evaluate the efficacy of...●AIM:To compare the success rate and complications of adjuvant use of mitomycin C and triamcinoloneimpregnated biodegradable nasal packing(TABP)in endoscopic dacryocystorhinostomy(DCR).And to evaluate the efficacy of combining intraoperative mitomycin C and TABP for endoscopic DCR.●METHODS:A total of 198 eyes of 148 patients who underwent endoscopic DCR for acquired nasolacrimal duct obstruction were retrospectively analysed.The patients were randomly divided into three groups:Group A included patients treated without intraoperative mitomycin C but with TABP,Group B included patients treated without triamcinolone but with intraoperative mitomycin C and normal saline-impregnated nasal packing,and Group C included patients treated with intraoperative mitomycin C and TABP.●RESULTS:The results revealed no significant difference in the overall success rates between Groups A(86.8%)and B(89.2%;P=0.377).However,Group C(97.5%)showed a significantly higher overall success rate than Groups A and B.The incidence of granulomas was significantly lower in group C(5%)than in Groups A(20.8%)and B(15.2%;P=0.009).Other complications,such as crust,synechiae,and revision surgery,did not differ significantly among the three groups.●CONCLUSION:The combination of intraoperative mitomycin C and TABP effectively prevents granulomas and enhances surgical success rate.Additionally,there is no statistically significant difference observed between the use of mitomycin C or TABP alone.展开更多
目的探讨黏膜黏附化疗药物HPC-MMC预防肿瘤复发的效果.方法对46例表浅膀胱癌患者于TURBt术后随机分两组行膀胱灌注化疗,黏膜黏附化疗药物组20例,以20 mg/20 ml 1%HPC-MMC膀胱灌注;MMC组26例,以20 mg/20 ml MMC膀胱灌注.疗程1年.HPC-MMC...目的探讨黏膜黏附化疗药物HPC-MMC预防肿瘤复发的效果.方法对46例表浅膀胱癌患者于TURBt术后随机分两组行膀胱灌注化疗,黏膜黏附化疗药物组20例,以20 mg/20 ml 1%HPC-MMC膀胱灌注;MMC组26例,以20 mg/20 ml MMC膀胱灌注.疗程1年.HPC-MMC组总灌注次数少于MMC组4次.随访6～36个月.结果 HPC-MMC组未发现出血性膀胱炎,无明显尿路刺激症状.平均随访27.4个月,7例复发,1年复发率为16.7%,3年总复发率38.9%.MMC组平均随访26.8个月,9例复发,1年复发率为22.7%,3年总复发率40.9%.结论黏膜黏附化疗药物HPC-MMC膀胱灌注防止肿瘤复发优于单用MMC,同时可降低副作用,减轻患者痛苦及经济负担.展开更多
In this paper,the preparation and properties of mitomycin C dextran-microspheres(MMC-DMS)were reported.The characteristics of pharmacokinetics and embolization effects of MMC-DMS in vivo were studied in dogs.The avera...In this paper,the preparation and properties of mitomycin C dextran-microspheres(MMC-DMS)were reported.The characteristics of pharmacokinetics and embolization effects of MMC-DMS in vivo were studied in dogs.The average diameter of the microspheres was 75±19μm and the content was 5% of MMC.In in vitro experiment, the release rate of drug demonstrated that the microspheres had sustained-release properties. The microspheres and conventional MMC were infused into the hepatic artery of dogs through a catheter for embolization,respectively.The plasma concentration of MMC was de- termined by HPLC.Results showed that the peak concentration of conventional MMC was 2.6 times as much as MMC-DMS.Angiograms revealed that peripheral blood vessels de- creased obviously in liver.The histopathologic examination showed that the microspheres lodged in the hepatic artery and displayed nodular necrosis in the embolized segment.The MMC-DMS were used in clinical trial in 100 patients with hepatic cancer.The tumor reduc- tion and improvement of symptoms in patients were observed after hepatic arterial embolization.The survival duration was prolonged.Results showed that the MMC-DMS is a promising embolic agent for treatment of hepatic cancer.It could aid in the use of intensive chemotherapy with minimum systemic side effect.展开更多
目的：评价联合应用丝裂霉素 C 和可调整缝线的小梁切除术治疗闭角型青光眼的效果。方法首次接受小梁切除的病例52例（52眼）,术中丝裂霉素C的浓度为0．2~0．4mg/mL,时间为2~4min,巩膜瓣两侧做2条可调整缝线。临床观察指标包括术后眼压...目的：评价联合应用丝裂霉素 C 和可调整缝线的小梁切除术治疗闭角型青光眼的效果。方法首次接受小梁切除的病例52例（52眼）,术中丝裂霉素C的浓度为0．2~0．4mg/mL,时间为2~4min,巩膜瓣两侧做2条可调整缝线。临床观察指标包括术后眼压、滤过泡、前房及并发症。结果所有病例平均随访（8．94±1．21）月,术后各时期的眼压与术前眼压比较均明显下降；无低压性黄斑病等严重并发症出现。结论青光眼小梁切除术中应用丝裂霉素C联合可调整缝线可以有效地降低患者的眼内压,稳定前房,减少术后并发症。展开更多
文摘●AIM:To compare the success rate and complications of adjuvant use of mitomycin C and triamcinoloneimpregnated biodegradable nasal packing(TABP)in endoscopic dacryocystorhinostomy(DCR).And to evaluate the efficacy of combining intraoperative mitomycin C and TABP for endoscopic DCR.●METHODS:A total of 198 eyes of 148 patients who underwent endoscopic DCR for acquired nasolacrimal duct obstruction were retrospectively analysed.The patients were randomly divided into three groups:Group A included patients treated without intraoperative mitomycin C but with TABP,Group B included patients treated without triamcinolone but with intraoperative mitomycin C and normal saline-impregnated nasal packing,and Group C included patients treated with intraoperative mitomycin C and TABP.●RESULTS:The results revealed no significant difference in the overall success rates between Groups A(86.8%)and B(89.2%;P=0.377).However,Group C(97.5%)showed a significantly higher overall success rate than Groups A and B.The incidence of granulomas was significantly lower in group C(5%)than in Groups A(20.8%)and B(15.2%;P=0.009).Other complications,such as crust,synechiae,and revision surgery,did not differ significantly among the three groups.●CONCLUSION:The combination of intraoperative mitomycin C and TABP effectively prevents granulomas and enhances surgical success rate.Additionally,there is no statistically significant difference observed between the use of mitomycin C or TABP alone.
文摘目的探讨黏膜黏附化疗药物HPC-MMC预防肿瘤复发的效果.方法对46例表浅膀胱癌患者于TURBt术后随机分两组行膀胱灌注化疗,黏膜黏附化疗药物组20例,以20 mg/20 ml 1%HPC-MMC膀胱灌注;MMC组26例,以20 mg/20 ml MMC膀胱灌注.疗程1年.HPC-MMC组总灌注次数少于MMC组4次.随访6～36个月.结果 HPC-MMC组未发现出血性膀胱炎,无明显尿路刺激症状.平均随访27.4个月,7例复发,1年复发率为16.7%,3年总复发率38.9%.MMC组平均随访26.8个月,9例复发,1年复发率为22.7%,3年总复发率40.9%.结论黏膜黏附化疗药物HPC-MMC膀胱灌注防止肿瘤复发优于单用MMC,同时可降低副作用,减轻患者痛苦及经济负担.
文摘In this paper,the preparation and properties of mitomycin C dextran-microspheres(MMC-DMS)were reported.The characteristics of pharmacokinetics and embolization effects of MMC-DMS in vivo were studied in dogs.The average diameter of the microspheres was 75±19μm and the content was 5% of MMC.In in vitro experiment, the release rate of drug demonstrated that the microspheres had sustained-release properties. The microspheres and conventional MMC were infused into the hepatic artery of dogs through a catheter for embolization,respectively.The plasma concentration of MMC was de- termined by HPLC.Results showed that the peak concentration of conventional MMC was 2.6 times as much as MMC-DMS.Angiograms revealed that peripheral blood vessels de- creased obviously in liver.The histopathologic examination showed that the microspheres lodged in the hepatic artery and displayed nodular necrosis in the embolized segment.The MMC-DMS were used in clinical trial in 100 patients with hepatic cancer.The tumor reduc- tion and improvement of symptoms in patients were observed after hepatic arterial embolization.The survival duration was prolonged.Results showed that the MMC-DMS is a promising embolic agent for treatment of hepatic cancer.It could aid in the use of intensive chemotherapy with minimum systemic side effect.
文摘目的：评价联合应用丝裂霉素 C 和可调整缝线的小梁切除术治疗闭角型青光眼的效果。方法首次接受小梁切除的病例52例（52眼）,术中丝裂霉素C的浓度为0．2~0．4mg/mL,时间为2~4min,巩膜瓣两侧做2条可调整缝线。临床观察指标包括术后眼压、滤过泡、前房及并发症。结果所有病例平均随访（8．94±1．21）月,术后各时期的眼压与术前眼压比较均明显下降；无低压性黄斑病等严重并发症出现。结论青光眼小梁切除术中应用丝裂霉素C联合可调整缝线可以有效地降低患者的眼内压,稳定前房,减少术后并发症。
